Filamin-A is essential for dopamine D2 receptor expression and signaling in tumorous lactotrophs

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 3, 2012, Pages 967-977

  Peverelli, Erika ^a   Mantovani, Giovanna ^a   Vitali, Eleonora ^a   Elli, Francesca M ^a   Olgiati, Luca ^a   Ferrero, Stefano ^a   Laws, Edward R ^b   Della Mina, Pamela ^c   Villa, Antonello ^c   Beck Peccoz, Paolo ^a   Spada, Anna ^a   Lania, Andrea G ^a,d  

^a UNIVERSITY OF MILAN   (Italy)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; FILAMIN A; PROLACTIN;

ANIMAL CELL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL CULTURE; CELL DIVISION; CELL STRAIN; CELL STRAIN GH3; CELL STRAIN MMQ; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; EPIGENETICS; GENE SILENCING; GENETIC TRANSFECTION; HORMONE INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROLACTIN RELEASE; PROLACTINOMA; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN METHYLATION; RAT; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; CELL PROLIFERATION; CONTRACTILE PROTEINS; HUMANS; LACTOTROPHS; MICROFILAMENT PROTEINS; PHOSPHORYLATION; PITUITARY NEOPLASMS; PROLACTINOMA; RATS; RECEPTORS, DOPAMINE D2; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

RATTUS;

EID: 84858052906     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-2902     Document Type: Article

References (34)

1. Ben-Jonathan N, Hnasko R 2001 Dopamine as a prolactin (PRL) inhibitor. Endocr Rev 22:724-763 (Pubitemid 34214293)
2. Molitch ME 2005 Pharmacologic resistance in prolactinomas patients. Pituitary 8:43-52
3. Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak CP, Kordon C, Peillon F, Jaquet P, Enjalbert A 1989 Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 69:500-509 (Pubitemid 19221218)
4. Passos VQ, Fortes MA, Giannella-Neto D, Bronstein MD 2009 Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonists. Neuroendocrinology 89:163-170
5. Caccavelli L, Feron F, Morange I, Rouer E, Benarous R, Dewailly D, Jaquet P, Kordon C, Enjalbert A 1994 Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology 60:314-322
6. Filopanti M, Barbieri AM, Angioni AR, Colao A, Gasco V, Grottoli S, Peri A, Baglioni S, Fustini MF, Pigliaru F, Monte PD, Borretta G, Ambrosi B, Jaffrain-Rea ML, Gasperi M, Brogioni S, Cannavò S, Mantovani G, Beck-Peccoz P, Lania A, Spada A 2008 Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas. Pharmacogenomics J 8:357-363
7. Friedman E, Adams EF, Höög A, Gejman PV, Carson E, Larsson C, De Marco L, Werner S, Fahlbusch R, Nordenskjöld M 1994 Normal structural dopamine type 2 receptor gene in prolactin-secreting and other pituitary tumors. J Clin Endocrinol Metab 78:568-574 (Pubitemid 24083293)
8. Li M, Bermak JC, Wang ZW, Zhou QY 2000 Modulation of dopamine D(2) receptor signaling by actin-binding protein (ABP-280). Mol Pharmacol 57:446-452 (Pubitemid 30140873)
9. Lin R, Karpa K, Kabbani N, Goldman-Rakic P, Levenson R 2001 Dopamine D2 and D3 receptors are linked to the actin cytoskeleton via interaction with filamin A. Proc Natl Acad Sci USA 98:5258- 5263
10. Lin R, Canfield V, Levenson R 2002 Dominant negative mutants of filamin A block cell surface expression of the D2 dopamine receptor. Pharmacology 66:173-181 (Pubitemid 36151393)
11. Lania AG, Mantovani G, Ferrero S, Pellegrini C, Bondioni S, Peverelli E, Braidotti P, Locatelli M, Zavanone ML, Ferrante E, Bosari S, Beck-Peccoz P, Spada A 2004 Proliferation of transformed somatotroph cells related to low or absent expression of protein kinase A regulatory subunit 1A protein. Cancer Res 64:9193-9198 (Pubitemid 40003794)
12. Peverelli E, Mantovani G, Calebiro D, Doni A, Bondioni S, Lania A, Beck-Peccoz P, Spada A 2008 The third intracellular loop of the human somatostatin receptor 5 is crucial for arrestin binding and receptor internalization after somatostatin stimulation. Mol Endocrinol 22:676-688 (Pubitemid 351397794)
13. Peverelli E, Olgiati L, Locatelli M, Magni P, Fustini MF, Frank G, Mantovani G, Beck-Peccoz P, Spada A, Lania A 2010 The dopamine- somatostatin chimeric compound BIM-23A760 exerts antiproliferative and cytotoxic effects in human non-functioning pituitary tumors by activating ERK1/2 and p38 pathways. Cancer Lett 288:170-176
14. Mantovani G, de Sanctis L, Barbieri AM, Elli FM, Bollati V, Vaira V, Labarile P, Bondioni S, Peverelli E, Lania AG, Beck-Peccoz P, Spada A 2010 Pseudohypoparathyroidism and GNAS epigenetic defects: clinical evaluation of Albright hereditary osteodystrophy and molecular analysis in 40 patients. J Clin Endocrinol Metab 95: 651-658
15. D'Addario M, Arora PD, Ellen RP, McCulloch CA 2003 Regulation of tension-induced mechano-transcriptional signals by the microtubule network in fibroblasts. J Biol Chem 278:53090-53097 (Pubitemid 38035912)
16. Iaccarino C, Samad TA, Mathis C, Kercret H, Picetti R, Borrelli E 2002 Control of lactotroph proliferation by dopamine: essential role of signaling through D2 receptors and ERKs. Proc Natl Acad Sci USA 99:14530-14535 (Pubitemid 35257705)
17. An JJ, Cho SR, Jeong DW, Park KW, Ahn YS, Baik JH 2003 Antiproliferative effects and cell death mediated by two isoforms of dopamine D2 receptors in pituitary tumor cells. Mol Cell Endocrinol 206:49-62 (Pubitemid 37011252)
18. Colao A, Savastano S 2011 Medical treatment of prolactinomas. Nat Rev Endocrinol 7:267-278
19. Zhang M, Breitwieser GE 2005 High affinity interaction with filamin A protects against calcium-sensing receptor degradation. J Biol Chem 280:11140-11146 (Pubitemid 40418420)
20. Seck T, Baron R, Horne WC 2003 Binding of filamin to the C-terminal tail of the calcitonin receptor controls recycling. J Biol Chem 278:10408-10416 (Pubitemid 36800306)
21. Thelin WR, Chen Y, Gentzsch M, Kreda SM, Sallee JL, Scarlett CO, Borchers CH, Jacobson K, Stutts MJ, Milgram SL 2007 Direct interaction with filamins modulates the stability and plasma membrane expression of CFTR. J Clin Invest 117:364-374 (Pubitemid 46203965)
22. Beekman JM, van der Poel CE, van der Linden JA, van den Berg DL, van den Berghe PV, van de Winkel JG, Leusen JH 2008 Filamin A stabilizes FcγRI surface expression and prevents its lysosomal routing. J Immunol 180:3938-3945
23. Vickery RG, von Zastrow M 1999 Distinct dynamin-dependent and -independent mechanisms target structurally homologous dopamine receptors to different endocytic membranes. J Cell Biol 144:31-43 (Pubitemid 29047009)
24. Heydorn A, Søndergaard BP, Hadrup N, Holst B, Haft CR, Schwartz TW 2004 Distinct in vitro interaction pattern of dopamine receptor subtypes with adaptor proteins involved in post-endocytotic receptor targeting. FEBS Lett 556:276-280 (Pubitemid 38058592)
25. Namkung Y, Dipace C, Urizar E, Javitch JA, Sibley DR 2009 G protein-coupled receptor kinase-2 constitutively regulates D2 dopamine receptor expression and signaling independently of receptor phosphorylation. J Biol Chem 284:34103-34115
26. Bartlett SE, Enquist J, Hopf FW, Lee JH, Gladher F, Kharazia V, Waldhoer M, Mailliard WS, Armstrong R, Bonci A, Whistler JL 2005 Dopamine responsiveness is regulated by targeted sorting of D2 receptors. Proc Natl Acad Sci USA 102:11521-11526 (Pubitemid 41153852)
27. Marley A, von Zastrow M 2010 Dysbindin promotes the post-endocytic sorting of G protein-coupled receptors to lysosomes. PLoS One 5:e9325
28. Scott MG, Pierotti V, Storez H, Lindberg E, Thuret A, Muntaner O, Labbé-Jullié C, Pitcher JA, Marullo S 2006 Cooperative regulation of extracellular signal-regulated kinase activation and cell shape change by filamin A and β-arrestins. Mol Cell Biol 26:3432-3445
29. Kim KM, Valenzano KJ, Robinson SR, Yao WD, Barak LS, Caron MG 2001 Differential regulation of the dopamine D2 and D3 receptors by G protein-coupled receptor kinases and β-arrestins. J Biol Chem 276:37409-37414
30. Meller E, Puza T, Miller JC, Friedhoff AJ, Schweitzer JW 1991 Receptor reserve for D2 dopaminergic inhibition of prolactin release in vivo and in vitro. J Pharmacol Exp Ther 257:668-675
31. Al-Azzawi H, Yacqub-Usman K, Richardson A, Hofland LJ, Clayton RN, Farrell WE 2011 Reversal of endogenous dopamine receptor silencing in pituitary cells augments receptor-mediated apoptosis. Endocrinology 152:364-373
32. Lania AG, Ferrero S, Pivonello R, Mantovani G, Peverelli E, Di Sarno A, Beck-Peccoz P, Spada A, Colao A 2010 Evolution of an aggressive prolactinoma into a growth hormone secreting pituitary tumor coincident with GNAS gene mutation. J Clin Endocrinol Metab 95:13-17
33. Xu Y, Bismar TA, Su J, Xu B, Kristiansen G, Varga Z, Teng L, Ingber DE, Mammoto A, Kumar R, Alaoui-Jamali MA 2010 Filamin A regulates focal adhesion disassembly and suppresses breast cancer cell migration and invasion. J Exp Med 207:2421-2437
34. Zhong Z, Yeow WS, Zou C, Wassell R, Wang C, Pestell RG, Quong JN, Quong AA 2010 Cyclin D1/cyclin-dependent kinase 4 interacts with filamin A and affects the migration and invasion potential of breast cancer cells. Cancer Res 70:2105-2114